Johns Hopkins Study Reveals Thirty-Eight Percent Higher Diabetes Risk for HIV Patients Switching to Integrase Inhibitor Treatments

Johns Hopkins study finds switching from protease inhibitors to integrase inhibitors is associated with an increased risk of diabetes in people living with HIV.

By: AXL Media

Published: Mar 31, 2026, 4:14 AM EDT

Source: Information for this report was sourced from Johns Hopkins Medicine

Evaluating Metabolic Shifts in Modern HIV Therapy

The landscape of HIV treatment has shifted significantly since 2015, with integrase strand transfer inhibitors (INSTIs) becoming the recommended first-line therapy due to their high efficacy and lower side-effect profile compared to older drugs. However, as the population of people living with HIV ages, metabolic complications like weight gain and insulin resistance have become more prevalent. A new study from Johns Hopkins Medicine indicates that the transition to these modern regimens may come with an unforeseen cost to metabolic health. Researchers found that adults who switched their medication from older protease inhibitors to newer integrase inhibitors faced a substantially higher probability of receiving a diabetes diagnosis.

Analyzing Data from a Massive North American Cohort

To reach these conclusions, researchers emulated a target clinical trial involving 13,071 adults across the United States and Canada between 2016 and 2022. The participants were all individuals without a prior history of diabetes who had been stable on older classes of HIV medication for at least six months. The team followed these patients for up to five years, comparing those who remained on their original protease or non-nucleoside reverse transcriptase inhibitors with those who transitioned to an integrase-based regimen. This large-scale analysis allowed the team to isolate the specific impact of the medication switch on the body's ability to regulate blood sugar.

Quantifying the Increased Risk of Diabetes Mellitus

The findings revealed a 38% higher risk of developing diabetes in patients who made the switch to integrase strand transfer inhibitors. Lead study author Dr. Yoseob Joseph Hwang suggests that this observation points to a direct adverse metabolic impact caused by the medication change itself. Importantly, this risk appears to be present regardless of whether the patient experienced significant weight gain, a common side effect often blamed for insulin resistance. This indicates that the inhibitors may interfere with glucose metabolism through biological pathways that are independent of simple changes in body mass index, necessitating a more nuanced approach to patient monitoring.